Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | VP, Finance & Accounting | March 15, 2021 | March 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEXICON PHARMACEUTICALS, INC.
Report date March 15, 2021 · Filed March 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,766 |
Ending reported balance
After 2021-03-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-03-15 · Sale · Disposed 10,912 · Balance 71,766 F1: Executed in multiple trades at prices ranging from $6.90 to $6.92 per share. The reported price reflects the weighted average sale price. Mr. Tessmer hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 2 · 2021-03-15 · Exercise / conversion · Acquired 12,000 · Balance 83,766 Row 3 · 2021-03-15 · Sale · Disposed 12,000 · Balance 71,766 F2: Executed in multiple trades at prices ranging from $6.91 to $6.955. The reported price reflects the weighted average sale price. Mr. Tessmer hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.31 · Expires 2030-02-06 | Direct | 50,980 |
Reported balance
After 2021-03-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-15 · Exercise / conversion · Disposed 12,000 · Balance 50,980 F3: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Executed in multiple trades at prices ranging from $6.90 to $6.92 per share. The reported price reflects the weighted average sale price. Mr. Tessmer hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Executed in multiple trades at prices ranging from $6.91 to $6.955. The reported price reflects the weighted average sale price. Mr. Tessmer hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2018 Filed Mar 2, 2018 22:11 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009733 · form4.xml · nonDerivative · entry 2 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:11 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 1,340 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009733 · form4.xml · nonDerivative · entry 1 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 22:15 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 18,970 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001127602-18-005207 · form4.xml · derivative · entry 2 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,970 Underlying: Common Stock · 18,970 shares Expires 2028-02-08 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/8/2019) and vests 1/48th per month for each month of service thereafter. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 22:15 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 12,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005207 · form4.xml · derivative · entry 1 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,640 Underlying: Common Stock · 12,640 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F2 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units (Phantom Stock) · Derivative | 2,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009398 · form4.xml · derivative · entry 9 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,225 Underlying: Common Stock · 2,075 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F6 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units (Phantom Stock) · Derivative | 2,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009398 · form4.xml · derivative · entry 8 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,336 Underlying: Common Stock · 2,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F5 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units (Phantom Stock) · Derivative | 1,339 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009398 · form4.xml · derivative · entry 7 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,340 Underlying: Common Stock · 1,339 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2015 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F4 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2015 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units (Phantom Stock) · Derivative | 857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009398 · form4.xml · derivative · entry 6 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 857 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2014 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2014 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 2,790 | $16.45 | $45,895.50 |
DisclosureSEC source: 0001127602-17-009398 · form4.xml · nonDerivative · entry 5 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,095 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009398 · form4.xml · nonDerivative · entry 4 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009398 · form4.xml · nonDerivative · entry 3 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 1,339 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009398 · form4.xml · nonDerivative · entry 2 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 23:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-009398 · form4.xml · nonDerivative · entry 1 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:28 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units (Phantom Stock) · Derivative | 5,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-005427 · form4.xml · derivative · entry 2 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,080 Underlying: Common Stock · 5,080 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:28 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 11,850 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001127602-17-005427 · form4.xml · derivative · entry 1 Tessmer James F · CIK 0001434095 · VP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,850 Underlying: Common Stock · 11,850 shares Expires 2027-02-09 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/9/2018) and vests 1/48th per month for each month of service thereafter Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.